Maxim Group reiterated their hold rating on shares of bluebird bio (NASDAQ:BLUE) in a research note published on Monday morning.

Other equities research analysts also recently issued research reports about the company. Cowen reiterated a buy rating on shares of bluebird bio in a report on Monday, August 6th. William Blair restated a buy rating on shares of bluebird bio in a report on Wednesday, September 5th. ValuEngine downgraded bluebird bio from a strong-buy rating to a buy rating in a report on Monday, September 17th. Goldman Sachs Group downgraded bluebird bio from a conviction-buy rating to a buy rating in a report on Friday, September 21st. Finally, Piper Jaffray Companies restated a buy rating on shares of bluebird bio in a report on Sunday, November 4th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and eighteen have assigned a buy rating to the company. bluebird bio has a consensus rating of Buy and an average price target of $200.80.

BLUE stock opened at $113.65 on Monday. The firm has a market capitalization of $6.72 billion, a P/E ratio of -14.74 and a beta of 2.37. bluebird bio has a 12-month low of $102.21 and a 12-month high of $236.17.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($2.73) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.90) by $0.17. The firm had revenue of $11.50 million for the quarter, compared to the consensus estimate of $6.90 million. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The company’s quarterly revenue was up 49.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.73) EPS. As a group, research analysts forecast that bluebird bio will post -10.57 earnings per share for the current fiscal year.

In related news, insider Philip D. Gregory sold 1,800 shares of the company’s stock in a transaction dated Monday, November 5th. The stock was sold at an average price of $137.38, for a total value of $247,284.00. Following the completion of the sale, the insider now directly owns 31,971 shares of the company’s stock, valued at approximately $4,392,175.98. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jeffrey T. Walsh sold 1,500 shares of the company’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $150.16, for a total value of $225,240.00. Following the completion of the sale, the insider now directly owns 36,995 shares of the company’s stock, valued at $5,555,169.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,600 shares of company stock worth $2,443,947. Company insiders own 3.00% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Belpointe Asset Management LLC purchased a new position in shares of bluebird bio during the 3rd quarter worth approximately $110,000. Vanguard Group Inc. increased its stake in bluebird bio by 10.1% in the 3rd quarter. Vanguard Group Inc. now owns 4,619,413 shares of the biotechnology company’s stock valued at $674,435,000 after purchasing an additional 422,866 shares in the last quarter. Legal & General Group Plc increased its stake in bluebird bio by 5.3% in the 3rd quarter. Legal & General Group Plc now owns 23,983 shares of the biotechnology company’s stock valued at $3,501,000 after purchasing an additional 1,201 shares in the last quarter. B. Riley Wealth Management Inc. purchased a new position in bluebird bio in the 3rd quarter valued at approximately $336,000. Finally, Neuberger Berman Group LLC increased its stake in bluebird bio by 16.0% in the 3rd quarter. Neuberger Berman Group LLC now owns 7,199 shares of the biotechnology company’s stock valued at $1,051,000 after purchasing an additional 991 shares in the last quarter.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.